CytomX Therapeutics (CTMX) stock
CTMX's Quality Score rose 1 point on Mon, Oct 5, to -6. Dipped under its 10-day low and closed back above it.
Follow CTMX's trial news. Pro members can get an alert when CytomX Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for CTMX, and how long its cash lasts
From CytomX Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 16 quarters
Dilution on the horizon
- Shelf registration (S-3ASR, filed Mar 16, 2026)
Insiders
CFO Christopher Ogden sold 1,624 shares on Jun 15. 4 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 33% in 3 months, 20% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−2Long-term trend below a falling 200-day average, down over one year
5 more things pulling CTMX's score down, for Pro members
Why CTMX lags the market
CytomX Therapeutics returned -47% over five years to the S&P 500's +91%; free cash flow went from $3.0M to -$75.8M.
2 drivers, the timeline, and the peer table, for Pro members
What's next
Expected to report Thu Nov 5, after the close
After its last 4 reports it closed +8.2% on average, higher 2 of 4 times.
What would turn CTMX's score around: 9 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
CTMX has 3 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1433.2
- MACD (12, 26, 9)Below signal
- 50-day average$3.19
- 200-day average$4.05
- ADX 1425.7
- Resistance$3.55
- Bollinger Bands (20, 2)Inside
- Volume0.4x
How CTMX ranks in Biotech
CTMX is #262 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
CRSPOpen for its score
CRVSOpen for its score
CTNMOpen for its score
CUEOpen for its score
CTMX3/14-6
When does CTMX report earnings, and what happens after?
Expected to report Thu Nov 5, after the close (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | -1.5% | +2.7% | -0.6% |
| May 7, 2026After close | After close | +1.0% | -0.5% | -5.5% |
| Mar 16, 2026Before open | Before open | +47.9% | +44.2% | -4.9% |
| Nov 6, 2025After close | After close | -9.3% | -13.6% | -7.9% |
Who is trading CTMX
CTMX insider trades
One insider sold $5K across 1 filing in the last 6 months. No open-market buys on record. The newest:
About CytomX Therapeutics
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of CTMX's score, with the points and the reason
- All 14 checks on CTMX and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on CTMX
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.